Astera Labs (NASDAQ:ALAB) Given New $210.00 Price Target at Morgan Stanley

Astera Labs (NASDAQ:ALAB) had its price target increased by equities researchers at Morgan Stanley from $200.00 to $210.00 in a report released on Wednesday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Morgan Stanley’s price objective would indicate a potential upside of 14.19% from the company’s current price.

Other analysts have also issued reports about the stock. Northland Securities lowered shares of Astera Labs from an “outperform” rating to a “market perform” rating and set a $120.00 price objective for the company. in a research note on Tuesday, July 22nd. Barclays restated an “equal weight” rating and set a $155.00 price objective on shares of Astera Labs in a research note on Monday, October 20th. Stifel Nicolaus raised their price objective on shares of Astera Labs from $185.00 to $200.00 and gave the company a “buy” rating in a research note on Wednesday. Deutsche Bank Aktiengesellschaft lifted their target price on Astera Labs from $160.00 to $200.00 and gave the stock a “buy” rating in a report on Tuesday, September 2nd. Finally, Citigroup lifted their target price on Astera Labs from $160.00 to $275.00 and gave the stock a “buy” rating in a report on Wednesday, September 17th. Thirteen analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, Astera Labs presently has a consensus rating of “Moderate Buy” and an average price target of $181.59.

Astera Labs Stock Performance

Shares of ALAB traded up $4.59 on Wednesday, reaching $183.90. The stock had a trading volume of 5,701,225 shares, compared to its average volume of 5,238,297. The firm has a market capitalization of $30.57 billion, a price-to-earnings ratio of 328.27, a price-to-earnings-growth ratio of 4.70 and a beta of 1.37. The company has a 50-day simple moving average of $196.79 and a 200-day simple moving average of $138.70. Astera Labs has a 12-month low of $47.13 and a 12-month high of $262.90.

Astera Labs (NASDAQ:ALAB) last released its earnings results on Tuesday, November 4th. The company reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.10. The company had revenue of $230.58 million during the quarter, compared to analysts’ expectations of $206.42 million. Astera Labs had a return on equity of 9.53% and a net margin of 16.54%.The firm’s revenue for the quarter was up 103.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.23 EPS. Astera Labs has set its Q4 2025 guidance at 0.50-0.510 EPS. On average, analysts expect that Astera Labs will post 0.34 EPS for the current fiscal year.

Insider Buying and Selling

In other Astera Labs news, Director Manuel Alba sold 183,000 shares of the business’s stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $173.27, for a total transaction of $31,708,410.00. Following the completion of the sale, the director owned 385,863 shares of the company’s stock, valued at approximately $66,858,482.01. The trade was a 32.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Michael Truett Tate sold 18,861 shares of the business’s stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $183.51, for a total value of $3,461,182.11. Following the sale, the chief financial officer directly owned 259,512 shares of the company’s stock, valued at $47,623,047.12. This represents a 6.78% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 1,092,997 shares of company stock valued at $192,231,120 over the last ninety days. 12.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Astera Labs

Several large investors have recently made changes to their positions in ALAB. Alliancebernstein L.P. lifted its position in shares of Astera Labs by 114.2% in the first quarter. Alliancebernstein L.P. now owns 8,401,019 shares of the company’s stock worth $501,289,000 after buying an additional 4,478,741 shares in the last quarter. Atreides Management LP raised its position in Astera Labs by 153.3% during the first quarter. Atreides Management LP now owns 4,652,264 shares of the company’s stock valued at $277,601,000 after purchasing an additional 2,815,614 shares during the period. Vanguard Group Inc. raised its position in Astera Labs by 29.6% during the second quarter. Vanguard Group Inc. now owns 12,049,223 shares of the company’s stock valued at $1,089,491,000 after purchasing an additional 2,751,747 shares during the period. FengHe Fund Management Pte. Ltd. purchased a new stake in Astera Labs during the second quarter valued at approximately $106,772,000. Finally, Bank of Nova Scotia raised its position in Astera Labs by 3,742.2% during the first quarter. Bank of Nova Scotia now owns 964,400 shares of the company’s stock valued at $57,546,000 after purchasing an additional 939,300 shares during the period. 60.47% of the stock is currently owned by hedge funds and other institutional investors.

About Astera Labs

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.